New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms
September 28, 2022 – Journal of Nuclear medicine, SNMMI
Research published in the Journal of Nuclear medicine suggested a novel PET radiotracer demonstrated efficacy in detecting a biomarker that indicates tumor aggressiveness in neuroendocrine neoplasms (NENs). The ability to accurately detect the uPAR biomarker may guide physicians to guide treatment decisions, in addition to identifying the biomarker as a potential therapeutic target for peptide Radionuclide therapy.
Copyright @JournalofNucMed
>> Read the article
The authors include Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, and Andreas Kjaer, Department of Clinical Physiology and Nuclear medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, and ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark; Seppo W. Langer,
ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark, Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; and Ulrich Knigge, ENETS Neuroendocrine Tumor Center of Excellence, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark, and Departments of Clinical Endocrinology and Surgical Gastroenterology, Copenhagen University Hospital- Rigshospitalet, Copenhagen, Denmark.
